Risks
4 risks
Risk Intelligence
Geopolitical tariff and supply chain uncertainties
View Risks →Alivus Life Sciences Limited — Q4 FY26
Alivus Life Sciences delivered a strong Q4 FY26 with revenue of 689 crore (+6.1% YoY) and EBITDA margin of 34.4% (+230 bps YoY), driven by favorable product mix, cost discipline, and non-GPL growth (71% of revenue).
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Alivus Life Sciences delivered a strong Q4 FY26 with revenue of 689 crore (+6.1% YoY) and EBITDA margin of 34.4% (+230 bps YoY), driven by favorable product mix, cost discipline, and non-GPL growth (71% of revenue). Full-year revenue reached 2,552 crore (+6.9% YoY) with EBITDA margin of 33.6% (+366 bps). Management guided EBITDA margins of 30-32% for FY27, citing backward integration benefits from Solapur (operational Q2 FY27) and sustained non-GPL momentum. Key risks include tariff uncertainties, raw material cost inflation from geopolitical tensions, and potential delays in CDMO deal closures.
अलिवस लाइफ साइंसेज ने चौथी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कमाई 689 करोड़ रुपये रही, जो पिछले साल से 6.1% ज्यादा है। मुनाफा (EBITDA) 34.4% रहा, जो पिछले साल से 2.3% बढ़ा। इसकी वजह अच्छा उत्पाद मिश्रण, खर्च पर नियंत्रण और जेनेरिक दवाओं के अलावा दूसरे उत्पादों की बिक्री (71% हिस्सा) है। पूरे साल की कमाई 2,552 करोड़ रुपये (+6.9%) और मुनाफा 33.6% रहा। अगले साल कंपनी 30-32% मुनाफा रखने का अनुमान लगा रही है, क्योंकि सोलापुर फैक्ट्री (अगले साल चालू) से लागत घटेगी। लेकिन टैरिफ अनिश्चितता, कच्चे माल की बढ़ती कीमत और CDMO सौदों में देरी जोखिम हैं।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Non-GPL revenue share
71%
+12pp YoY
Non-GPL segment contribution increased from 59% in FY22 to 71% in FY26, reducing dependence on GPL.
Gross margin
60.7%
+420bps YoY
Gross margin expanded 420 bps YoY to 60.7% in Q4, driven by new launches and product mix.
Customer base
900+
+49 customers in FY26
Added 49 new customers during FY26, taking total customer base to over 900.
High potency API pipeline
28 products
+12 validated
High potency API pipeline has 28 products; 12 validated, 7 in advanced stages. Patent expiries from 2028.
What Changed vs Last Quarter
NEW
Capex of ~540 crore in FY27 funded internally
Planned capex of about 540 crore for FY27, including carryover commitments and fresh investments, fully funded through internal accruals.
NEW
Solapur Phase 1 operational in Q2 FY27
Solapur greenfield facility Phase 1 expected to be operational in Q2 of FY27, with initial capacity utilization of 40-50%.
UPDATED
EBITDA margin guidance of 30-32% for FY27
Management expects to sustain EBITDA margins in the range of 30-32% for FY27, despite geopolitical headwinds.
UPDATED
Two new CDMO deals expected in early H2 FY27
Management expects to close two new CDMO deals in the early second half of FY27, continuing momentum.
DROPPED
Revenue growth: high single-digit for FY26
Management expects high single-digit revenue growth for FY26, driven by non-GPL segment and CDMO ramp-up.
DROPPED
Capex guidance reduced to ₹450 crore for FY26
Capex for FY26 now guided at ₹450 crore, down from ₹600 crore, with ₹150 crore deferred to FY27.
NEW RISK
Geopolitical tariff and supply chain uncertainties
Ongoing geopolitical conflicts and tariff uncertainties could disrupt supply chains and increase logistics and energy costs.
NEW RISK
Raw material cost inflation from war
Solvent costs have increased significantly due to the war, though management expects to pass on costs to customers.
NEW RISK
Fire incident at H plant impact
A fire at the H plant impacted intermediate production, resulting in a 20 crore loss booked in other expenses, with minor spillover expected in Q1.
NEW RISK
Potential delays in CDMO deal closures
Management moderated timing for two CDMO deals to early H2 FY27, indicating possible delays from earlier expectations.
RISK GONE
Geopolitical instability impacting global business
Management highlighted geopolitical risks as a key concern given the company's international presence, though diversification mitigates impact.
RISK GONE
CDMO growth slower than peers due to smaller deal sizes
Analyst questioned why CDMO deal sizes are limited to $4-6M vs peers targeting $50-100M; management defended strategy citing high attrition and tax-driven manufacturing in Ireland.
RISK GONE
Pricing erosion in mature molecules
Management acknowledged 4-4.5% annual price erosion across the portfolio, but expects to offset via next-gen processes and new launches.
RISK GONE
Sholapur capacity delay and scale-down
Sholapur plant delayed by ~3 months to July 2026, and initial capacity reduced from 600kL to 450-500kL, though management says it won't impact growth.
🤫 Topics management stopped discussing
Mentioned in Q2 FY26, Q3 FY26
Capex for FY26 now guided at ₹450 crore, down from ₹600 crore, with ₹150 crore deferred to FY27.
Mentioned in Q2 FY26, Q3 FY26
Management expects high single-digit revenue growth for FY26, driven by non-GPL segment and CDMO ramp-up.
Fast read
Guidance and risk preview
Management expects to sustain EBITDA margins in the range of 30-32% for FY27, despite geopolitical headwinds.
Ongoing geopolitical conflicts and tariff uncertainties could disrupt supply chains and increase logistics and energy costs.
View Risks →